Literature DB >> 1969038

Pentoxifylline and wellbeing in patients with cancer.

B J Dezube, J L Fridovich-Keil, I Bouvard, R F Lange, A B Pardee.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1969038     DOI: 10.1016/0140-6736(90)90450-j

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

1.  Pentoxifylline decreases in vivo and in vitro tumour necrosis factor-alpha (TNF-alpha) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL).

Authors:  E P Sampaio; M O Moraes; J A Nery; A R Santos; H C Matos; E N Sarno
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

2.  Therapeutic potential for cytokine antagonists: Thalidomide and pentoxifylline in Hansen's disease.

Authors:  T C Peterson
Journal:  Can J Infect Dis       Date:  1995-01

3.  Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients: a pilot study.

Authors:  B J Dezube; M L Sherman; J L Fridovich-Keil; J Allen-Ryan; A B Pardee
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

4.  Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease.

Authors:  S Furukawa; T Matsubara; Y Umezawa; T Motohashi; T Ino; K Yabuta
Journal:  Eur J Pediatr       Date:  1994-09       Impact factor: 3.183

Review 5.  Management of cancer anorexia/cachexia.

Authors:  C L Loprinzi
Journal:  Support Care Cancer       Date:  1995-03       Impact factor: 3.603

6.  Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents.

Authors:  G D Martich; R L Danner; M Ceska; A F Suffredini
Journal:  J Exp Med       Date:  1991-04-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.